1
|
Eckert MJ and Martin MJ: Trauma: Spinal
cord injury. Surg Clin North Am. 97:1031–1045. 2017.PubMed/NCBI View Article : Google Scholar
|
2
|
Hamid R, Averbeck MA, Chiang H, Garcia A,
Al Mousa RT, Oh SJ, Patel A, Plata M and Del Popolo G: Epidemiology
and pathophysiology of neurogenic bladder after spinal cord injury.
World J Urol. 36:1517–1527. 2018.PubMed/NCBI View Article : Google Scholar
|
3
|
Witiw CD and Fehlings MG: Acute spinal
cord injury. J Spinal Disord Tech. 28:202–210. 2015.PubMed/NCBI View Article : Google Scholar
|
4
|
Kumar R, Lim J, Mekary RA, Rattani A,
Dewan MC, Sharif SY, Osorio-Fonseca E and Park KB: Traumatic spinal
injury: Global epidemiology and worldwide volume. World Neurosurg.
113:e345–e363. 2018.PubMed/NCBI View Article : Google Scholar
|
5
|
Kjell J and Olson L: Rat models of spinal
cord injury: From pathology to potential therapies. Dis Model Mech.
9:1125–1137. 2016.PubMed/NCBI View Article : Google Scholar
|
6
|
Fan Q, Cavus O, Xiong L and Xia Y: Spinal
cord injury: How could acupuncture help? J Acupunct Meridian Stud.
11:124–132. 2018.PubMed/NCBI View Article : Google Scholar
|
7
|
Varma AK, Das A, Wallace G IV, Barry J,
Vertegel AA, Ray SK and Banik NL: Spinal cord injury: A review of
current therapy, future treatments, and basic science frontiers.
Neurochem Res. 38:895–905. 2013.PubMed/NCBI View Article : Google Scholar
|
8
|
Cristante AF, Filho TE, Marcon RM, Letaif
OB and Rocha ID: Therapeutic approaches for spinal cord injury.
Clinics (Sao Paulo). 67:1219–1224. 2012.PubMed/NCBI View Article : Google Scholar
|
9
|
Ravikumar K and Sridhar B: Lenalidomide,
an antineoplastic drug, and its hemihydrate. Acta Crystallogr C.
65:o502–o505. 2009.PubMed/NCBI View Article : Google Scholar
|
10
|
Weisel K and Kanz L: Lenalidomide. Recent
Results Cancer Res. 201:347–357. 2014.PubMed/NCBI View Article : Google Scholar
|
11
|
Valera E, Mante M, Anderson S, Rockenstein
E and Masliah E: Lenalidomide reduces microglial activation and
behavioral deficits in a transgenic model of Parkinson's disease. J
Neuroinflammation. 12(93)2015.PubMed/NCBI View Article : Google Scholar
|
12
|
Mosley RL and Gendelman HE: Control of
neuroinflammation as a therapeutic strategy for amyotrophic lateral
sclerosis and other neurodegenerative disorders. Exp Neurol.
222:1–5. 2010.PubMed/NCBI View Article : Google Scholar
|
13
|
Yamamoto K, Kitawaki T, Sugimoto N, Fujita
H, Kawase Y, Takaori-Kondo A and Kadowaki N: Anti-inflammatory
modulation of human myeloid-derived dendritic cell subsets by
lenalidomide. Immunol Lett. 211:41–48. 2019.PubMed/NCBI View Article : Google Scholar
|
14
|
Ding W, Zeng T, Tao W, Ge W, Deng V, Lei
H, Xiao Y and Liao F: Effect of lenalidomide on the human gastric
cancer cell line SGC7901/vincristine notch signaling. J Cancer Res
Ther. 14:S237–S242. 2018.PubMed/NCBI View Article : Google Scholar
|
15
|
Guo J, Fei C, Zhao Y, Zhao S, Zheng Q, Su
J, Wu D, Li X and Chang C: Lenalidomide restores the osteogenic
differentiation of bone marrow mesenchymal stem cells from multiple
myeloma patients via deactivating notch signaling pathway.
Oncotarget. 8:55405–55421. 2017.PubMed/NCBI View Article : Google Scholar
|
16
|
Yi G, Liu L, Lv C, Wei Y and Yan T:
Ginsenoside Rg1 defenses PC-12cells against hydrogen
peroxide-caused damage via up-regulation of miR-216a-5p. Life Sci.
236(116948)2019.PubMed/NCBI View Article : Google Scholar
|
17
|
Wen F, Wong HK, Tay CY, Yu H, Li H, Yu T,
Tijore A, Boey FY, Venkatraman SS and Tan LP: Induction of myogenic
differentiation of human mesenchymal stem cells cultured on notch
agonist (Jagged-1) modified biodegradable scaffold surface. ACS
Appl Mater Interfaces. 6:1652–1661. 2014.PubMed/NCBI View Article : Google Scholar
|
18
|
Yue JK, Chan AK, Winkler EA, Upadhyayula
PS, Readdy WJ and Dhall SS: A review and update on the guidelines
for the acute management of cervical spinal cord injury-part II. J
Neurosurg Sci. 60:367–384. 2016.PubMed/NCBI
|
19
|
Siriphorn A, Chompoopong S and Floyd CL:
17β-estradiol protects Schwann cells against
H2O2-induced cytotoxicity and increases
transplanted Schwann cell survival in a cervical hemicontusion
spinal cord injury model. J Neurochem. 115:864–872. 2010.PubMed/NCBI View Article : Google Scholar
|
20
|
Li X, Zhan J, Hou Y, Hou Y, Chen S, Luo D,
Luan J, Wang L and Lin D: Coenzyme Q10 regulation of apoptosis and
oxidative stress in H2O2 induced BMSC death
by modulating the Nrf-2/NQO-1 signaling pathway and its application
in a model of spinal cord injury. Oxid Med Cell Longev.
2019(6493081)2019.PubMed/NCBI View Article : Google Scholar
|
21
|
Talati C, Sallman D and List A:
Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond.
Semin Hematol. 54:159–166. 2017.PubMed/NCBI View Article : Google Scholar
|
22
|
Flowers CR, Leonard JP and Fowler NH:
Lenalidomide in follicular lymphoma. Blood. 135:2133–2136.
2020.PubMed/NCBI View Article : Google Scholar
|
23
|
Jia Z, Zhu H, Li J, Wang X, Misra H and Li
Y: Oxidative stress in spinal cord injury and antioxidant-based
intervention. Spinal Cord. 50:264–274. 2012.PubMed/NCBI View Article : Google Scholar
|
24
|
Hall ED: Antioxidant therapies for acute
spinal cord injury. Neurotherapeutics. 8:152–167. 2011.PubMed/NCBI View Article : Google Scholar
|
25
|
Zhu X, Jiang S, Hu N, Luo F, Dong H, Kang
YM, Jones KR, Zou Y, Xiong L and Ren J: Tumour necrosis
factor-alpha inhibition with lenalidomide alleviates tissue
oxidative injury and apoptosis in ob/ob obese mice. Clin Exp
Pharmacol Physiol. 41:489–501. 2014.PubMed/NCBI View Article : Google Scholar
|
26
|
Li L, Hua Y, Dong M, Li Q, Smith DT, Yuan
M, Jones KR and Ren J: Short-term lenalidomide (Revlimid)
administration ameliorates cardiomyocyte contractile dysfunction in
ob/ob obese mice. Obesity (Silver Spring). 20:2174–2185.
2012.PubMed/NCBI View Article : Google Scholar
|
27
|
Eitan E, Hutchison ER, Greig NH, Tweedie
D, Celik H, Ghosh S, Fishbein KW, Spencer RG, Sasaki CY, Ghosh P,
et al: Combination therapy with lenalidomide and nanoceria
ameliorates CNS autoimmunity. Exp Neurol. 273:151–160.
2015.PubMed/NCBI View Article : Google Scholar
|
28
|
Zhang N, Yin Y, Xu SJ, Wu YP and Chen WS:
Inflammation & apoptosis in spinal cord injury. Indian J Med
Res. 135:287–296. 2012.PubMed/NCBI
|
29
|
Keane RW, Davis AR and Dietrich WD:
Inflammatory and apoptotic signaling after spinal cord injury. J
Neurotrauma. 23:335–344. 2006.PubMed/NCBI View Article : Google Scholar
|
30
|
Qu X, Mei J, Yu Z, Zhai Z, Qiao H and Dai
K: Lenalidomide regulates osteocytes fate and related
osteoclastogenesis via IL-1β/NF-kappaB/RANKL signaling. Biochem
Biophys Res Commun. 501:547–555. 2018.PubMed/NCBI View Article : Google Scholar
|
31
|
Cai Z, Zhao B, Deng Y, Shangguan S, Zhou
F, Zhou W, Li X, Li Y and Chen G: Notch signaling in
cerebrovascular diseases (Review). Mol Med Rep. 14:2883–2898.
2016.PubMed/NCBI View Article : Google Scholar
|
32
|
Wei H, Huang L, Wei F, Li G, Huang B, Li J
and Cao C: 2020. Up-regulation of miR-139-5p protects diabetic mice
from liver tissue damage and oxidative stress through inhibiting
notch signaling pathway. Acta Biochim Biophys Sin (Shanghai).
52:390–400. 2016.PubMed/NCBI View Article : Google Scholar
|
33
|
Zhang S, Botchway BOA, Zhang Y and Liu X:
Resveratrol can inhibit notch signaling pathway to improve spinal
cord injury. Ann Anat. 223:100–107. 2019.PubMed/NCBI View Article : Google Scholar
|
34
|
Zhang Y, Gao T, Li X, Wen CC, Yan XT, Peng
C and Xiao Y: Circ_0005075 targeting miR-151a-3p promotes
neuropathic pain in CCI rats via inducing NOTCH2
expression. Gene. 767(145079)2021.PubMed/NCBI View Article : Google Scholar
|